Showing results (1-10 of 120) with videos related to
Sort By:
Pageof 12
Plos One|November 14, 2013
Quantifying clinical HPV4 dose inefficiencies in a safety net populationDiane M Harper, Inge Verdenius, Felicia Ratnaraj, et al.Preventive Medicine|January 21, 2014
The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose seriesDiane M Harper, Inge Verdenius, George D Harris, et al.Plos One|July 31, 2014
In a safety net population HPV4 vaccine adherence worsens as BMI increasesDiane M Harper, Britney M Else, Mitchell J Bartley, et al.Plos One|August 17, 2013
Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US MidwestInge Verdenius, Diane M Harper, George D Harris, et al.Public Health Genomics|August 18, 2009
Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public healthDiane M HarperGynecologic Oncology|July 25, 2008
Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of ageDiane M HarperCurrent Opinion in Obstetrics & Gynecology|November 20, 2009
Current prophylactic HPV vaccines and gynecologic premalignanciesDiane M HarperExpert Review of Vaccines|December 1, 2009
Currently approved prophylactic HPV vaccinesDiane M HarperPlos One|May 13, 2014
Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion ratesKelly Jo Sandri, Inge Verdenius, Mitchell J Bartley, et al.Pageof 12